For cisplatin ineligible patients with locally advanced head and neck cancer, would you consider RT + immunotherapy rather than RT + cetuximab?

In light of recent trials showing no difference in outcomes with RT+cetuximab vs RT+IO, does this potentially lead us to use immunotherapy in cisplatin-ineligible patients? IO is typically easier to administer and manage than cetuximab. Can we extrapolate this from the trials? (GORTEC 2015-01) NRG-HN004